Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MBX Biosciences, Inc. ( (MBX) ) has issued an update.
On May 11, 2026, MBX Biosciences reported preliminary blinded Phase 1 data for its dual GLP-1/GIP prodrug MBX 4291 in adults with obesity, showing dose-proportional pharmacokinetics, a slow-release profile compatible with once-monthly dosing, and mean weight loss of about 7% at eight weeks in the first multiple ascending dose cohort, with mostly mild gastrointestinal events and no serious safety signals. The company also broadened its obesity franchise by nominating MBX 5765 as a lead amycretin prodrug candidate, advancing a GLP-1/GIP/glucagon triple-agonist program, and announcing proof-of-concept Phase 2a data for imapextide in post-bariatric hypoglycemia, while opting not to fund a Phase 2b imapextide trial as it reallocates resources toward its obesity pipeline and lead hypoparathyroidism therapy canvuparatide.
The most recent analyst rating on (MBX) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on MBX Biosciences, Inc. stock, see the MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and worsening cash burn), partially offset by a strong balance sheet with very low leverage. Technically, the stock shows strong uptrend momentum but is overbought, increasing pullback risk. Recent corporate events are constructive due to regulatory progress and Phase 3 planning, while valuation remains constrained by ongoing losses and no dividend.
To see Spark’s full report on MBX stock, click here.
More about MBX Biosciences, Inc.
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP platform. Its pipeline targets conditions such as obesity and chronic hypoparathyroidism, addressing large, unmet medical needs in markets where incretin-based and other hormone-modulating drugs are rapidly expanding.
Average Trading Volume: 533,187
Technical Sentiment Signal: Buy
Current Market Cap: $1.95B
See more data about MBX stock on TipRanks’ Stock Analysis page.